Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant

Tundra lists 1 Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

SUSPENDED

NCT06860594

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-13

18 states

Astrocytoma, IDH-Mutant, Grade 2

Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant

Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant